These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 14209494)

  • 1. SIMPLIFIED TURBIDIMETRIC ASSAY OF LIPASE IN DOSAGE FORMS.
    SIEGEL FP; ECANOW B
    J Pharm Sci; 1964 Jul; 53():831-2. PubMed ID: 14209494
    [No Abstract]   [Full Text] [Related]  

  • 2. STABILITY PATTERNS OF VITAMIN A IN VARIOUS PHARMACEUTICAL DOSAGE FORMS.
    CARSTENSEN JT
    J Pharm Sci; 1964 Jul; 53():839-40. PubMed ID: 14209498
    [No Abstract]   [Full Text] [Related]  

  • 3. Coating of pharmaceutical powders by fluidized bed process. II. Microcapsules produced by layering of fine powder on coarse particles and subsequent aqueous enteric coating.
    Fukumori Y; Yamaoka Y; Ichikawa H; Fukuda T; Takeuchi Y; Osako Y
    Chem Pharm Bull (Tokyo); 1988 Apr; 36(4):1491-501. PubMed ID: 3416369
    [No Abstract]   [Full Text] [Related]  

  • 4. A "GO, NO-GO" ASSAY PROCEDURE FOR RESIDUAL AMOUNTS OF ACETONE IN FILM-COATED TABLETS.
    HOLL WW; MICHAELS TP; SINOTTE LP
    J Pharm Sci; 1963 Aug; 52():817-8. PubMed ID: 14060474
    [No Abstract]   [Full Text] [Related]  

  • 5. Formulation and in vitro and in vivo availability of diclofenac sodium enteric-coated beads.
    Hosny EA; el-Mahrouk GM; Gouda MW
    Drug Dev Ind Pharm; 1998 Jul; 24(7):661-6. PubMed ID: 9876511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of dissolution tests for fexofenadine hydrochloride capsules and coated tablets.
    Breier AR; Paim CS; Steppe M; Schapoval EE
    J Pharm Pharm Sci; 2005 Aug; 8(2):289-98. PubMed ID: 16124939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RELATIONSHIP BETWEEN RATE OF DISSOLUTION, DISINTEGRATION TIME, AND PHYSIOLOGICAL AVAILABILITY OF RIBOFLAVIN IN SUGAR-COATED TABLETS.
    MIDDLETON EJ; DAVIES JM; MORRISON AB
    J Pharm Sci; 1964 Nov; 53():1378-80. PubMed ID: 14253600
    [No Abstract]   [Full Text] [Related]  

  • 9. DOSAGE FORMS FOR USE IN ORAL THERAPEUTICS.
    BERNSTEIN HB; SCHEINDLIN S
    J Oral Ther Pharmacol; 1964 Jul; 1():99-105. PubMed ID: 14204422
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease.
    de Montalembert M; Bachir D; Hulin A; Gimeno L; Mogenet A; Bresson JL; Macquin-Mavier I; Roudot-Thoraval F; Astier A; Galactéros F
    Haematologica; 2006 Dec; 91(12):1685-8. PubMed ID: 17145606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of enteric coated tablet sensitive to pancreatic lipase. I. In vitro disintegration test.
    Yoshitomi H; Shizuku Y; Masuda Y; Itakura R; Kanke M; Okamoto S; Nashihata T; Goto S
    Chem Pharm Bull (Tokyo); 1992 Jul; 40(7):1902-5. PubMed ID: 1394712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissolution evaluation of marketed tetracyclines solid oral dosage forms.
    Yamamoto CH; Pinto Tde J; Alves MS
    Boll Chim Farm; 2000; 139(2):81-4. PubMed ID: 10920533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic inequivalence of pharmaceutical alternates.
    Levy RA
    Am Pharm; 1985 Apr; NS25(4):28-39. PubMed ID: 3893084
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral dosage forms.
    Prescrire Int; 2014 Sep; 23(152):212-3. PubMed ID: 25325122
    [No Abstract]   [Full Text] [Related]  

  • 15. EXTRAPOLATION OF APPEARANCE OF TABLETS AND POWDERS FROM ACCELERATED STORAGE TESTS.
    CARSTENSEN JT; JOHNSON JB; VALENTINE JW; VANCE JJ
    J Pharm Sci; 1964 Sep; 53():1050-4. PubMed ID: 14234893
    [No Abstract]   [Full Text] [Related]  

  • 16. Current perspectives in dissolution testing of conventional and novel dosage forms.
    Azarmi S; Roa W; Löbenberg R
    Int J Pharm; 2007 Jan; 328(1):12-21. PubMed ID: 17084051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy of exocrine pancreatic insufficiency in man. Relations between in vitro enzyme activities and in vivo potency in commercial pancreatic extracts.
    Graham DY
    N Engl J Med; 1977 Jun; 296(23):1314-7. PubMed ID: 16212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COMPRESSION OF PHARMACEUTICAL POWDERS. I. THEORY AND INSTRUMENTATION.
    SHLANTAS JR; MILOSOVICH G
    J Pharm Sci; 1964 May; 53():562-4. PubMed ID: 14193895
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison between the U.S.P. 18 and the wet sieving disintegration tests.
    Sandell E; Helmstein I
    Acta Pharm Suec; 1971 Nov; 8(5):549-52. PubMed ID: 5159524
    [No Abstract]   [Full Text] [Related]  

  • 20. [EFFECT OF DOSAGE FORMS ON THE ABSORPTION OF DRUGS].
    FINHOLT P
    Sven Farm Tidskr; 1964 Apr; 58():311-7 CONTD. PubMed ID: 14147392
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.